Bristol Myers Squibb became the latest large drugmaker to sue the federal government over a plan to change how it doles out ...

We recently published a list of 10 Stocks That Are Close To Becoming Dividend Aristocrats. In this article, we are going to ...

Bristol-Myers Squibb can probably continue to grow for a long time. Its dividend looks to be sustainable at the moment. But ...

Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...

The outlay, plus up to $1.1 billion in milestones, has secured Takeda ex-China rights to a molecule that could compete with ...

Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to ...

The moves will affect more than 300 employees across both companies as both firms look to drive growth in the long term.

Cost-effectiveness agency NICE has recommended NHS use of the therapy – called Kimmtrak (tebentafusp) – for the treatment of ...

RWJBarnabas Health appoints Steven Stylianos, MD as system director for pediatric surgery and surgeon-in-chief at Bristol-Myers Squibb Children's Hospital ...

Despite billions poured into research, new medicines still typically take a decade or more to develop.